Y-mAbs to Announce Third Quarter 2023 Financial and Operating Results on November 13, 2023
31 Ottobre 2023 - 12:05PM
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:
YMAB) today announced that it will report its financial results for
the third quarter ended September 30, 2023, on Monday, November 13,
2023, after the close of the U.S. financial markets. The
announcement will be followed by a conference call and webcast with
the investment community on Tuesday, November 14, 2023, at 9:00
a.m. ET. Participating on the call from Y-mAbs will be Michael
Rossi, President and Chief Executive Officer; Thomas Gad, Founder,
Vice Chair and Chief Business Officer; Bo Kruse, Chief Financial
Officer; Sue Smith, Chief Commercial Officer; Steen Lisby, Chief
Scientific Officer; and Vignesh Rajah, Chief Medical Officer.
Conference call and webcast
details:
Investors
(domestic): |
877-407-0792 |
Investors (international): |
201-689-8263 |
Conference ID: |
13741478 |
|
|
To access a live webcast of the update, please
use this link.
About Y-mAbsY-mAbs is a
commercial-stage biopharmaceutical company focused on the
development and commercialization of novel, antibody-based
therapeutic cancer products. In addition to conventional
antibodies, the Company’s technologies include bispecific
antibodies generated using the Y-BiClone platform and the SADA
platform. The Company’s broad and advanced product pipeline
includes one FDA-approved product, DANYELZA® (naxitamab-gqgk),
which targets tumors that express GD2, and one product candidate at
the registration stage, OMBLASTYS® (omburtamab), which targets
tumors that express B7-H3.
Forward-Looking StatementsSuch
statements include, but are not limited to, statements about the
Company’s management and business model, including the Company’s
plans and strategies, development, commercialization and product
distribution plans, including the Company’s ability to build
world-class capabilities and develop and commercialize new
innovative treatments that improve the lives of patients with
cancer; expectations with respect to the Company’s products and
product candidates, including the potential of DANYELZA and product
candidates based on the SADA technology and the potential benefits
thereof, including with respect to expansion of the commercial
footprint of DANYELZA as well as bringing forward novel SADA
constructs for cancer patients; and other statements that are not
historical facts. Words such as ‘‘anticipate,’’ ‘‘believe,’’
“contemplate,” ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’
“hope,” ‘‘intend,’’ ‘‘may,’’ ‘‘might,’’ ‘‘plan,’’ ‘‘potential,’’
‘‘predict,’’ ‘‘project,’’ ‘‘should,’’ ‘‘target,’’ “will”,
‘‘would’’, “guidance,” and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. The
Company’s product candidates and related technologies are novel
approaches to cancer treatment that present significant challenges.
Actual results may differ materially from those indicated by such
forward-looking statements as a result of various factors,
including but not limited to: risks associated with the Company’s
financial condition and need for additional capital; the risks that
actual results of the Company’s restructuring plan and revised
business plan will not be as expected; risks associated with the
Company’s development work; cost and success of the Company’s
product development activities and clinical trials; the risks of
delay in the timing of the Company’s regulatory submissions or
failure to receive approval of the Company’s drug candidates; the
risks related to commercializing any approved pharmaceutical
product including the rate and degree of market acceptance of the
Company’s product candidates; development of the Company’s sales
and marketing capabilities and risks associated with failure to
obtain sufficient reimbursement for the Company’s products; the
risks related to the Company’s dependence on third parties
including for conduct of clinical testing and product manufacture;
the Company’s inability to enter into partnerships; the risks
related to government regulation; risks related to market approval,
risks associated with protection of the Company’s intellectual
property rights; risks related to employee matters and managing
growth; risks related to the Company’s common stock, risks
associated with macroeconomic conditions, including the conflict
between Russia and Ukraine and sanctions related thereto,
inflation, increased interest rates, uncertain global credit and
capital markets and disruptions in banking systems; and other risks
and uncertainties affecting the Company including those described
in the "Risk Factors" section included in the Company’s Annual
Report on Form 10-K for the fiscal year ended December 31, 2022,
the Company’s Quarterly Report on Form 10-Q for the quarter ended
March 31, 2023, the Company’s Quarterly Report on Form 10-Q for the
quarter ended June 30, 2023 and future filings and reports by the
Company. Any forward-looking statements contained in this press
release speak only as of the date hereof, and the Company
undertakes no obligation to update any forward-looking statement,
whether as a result of new information, future events or
otherwise.DANYELZA®, OMBLASTYS® and Y-mAbs® are registered
trademarks of Y-mAbs Therapeutics, Inc.
Investor Contact:
Courtney DuganVP, Head of Investor Relationscdu@ymabs.com
Grafico Azioni Y mAbs Therapeutics (NASDAQ:YMAB)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Y mAbs Therapeutics (NASDAQ:YMAB)
Storico
Da Set 2023 a Set 2024